{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T19:26:00Z","timestamp":1771269960145,"version":"3.50.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,3,12]],"date-time":"2022-03-12T00:00:00Z","timestamp":1647043200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,3,12]],"date-time":"2022-03-12T00:00:00Z","timestamp":1647043200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100018936","name":"Universit\u00e4tsklinikum Heidelberg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100018936","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs Aging"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1007\/s40266-022-00928-z","type":"journal-article","created":{"date-parts":[[2022,3,12]],"date-time":"2022-03-12T10:02:53Z","timestamp":1647079373000},"page":"251-256","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Drug Treatment of Hypercholesterolemia in Older Adults: Focus on Newer Agents"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3005-0546","authenticated-orcid":false,"given":"Felicitas","family":"Stoll","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annette","family":"Eidam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lola","family":"Michael","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00fcrgen M.","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Walter E.","family":"Haefeli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,3,12]]},"reference":[{"issue":"1","key":"928_CR1","doi-asserted-by":"publisher","first-page":"e0201196","DOI":"10.1371\/journal.pone.0201196","volume":"14","author":"HF Hope","year":"2019","unstructured":"Hope HF, Binkley GM, Fenton S, et al. Systematic review of the predictors of statin adherence for the primary prevention of cardiovascular disease. PLoS ONE. 2019;14(1):e0201196.","journal-title":"PLoS ONE"},{"issue":"10263","key":"928_CR2","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1016\/S0140-6736(20)32332-1","volume":"396","author":"B Gencer","year":"2020","unstructured":"Gencer B, Marston NA, Im K, et al. Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomised controlled trials. Lancet. 2020;396(10263):1637\u201343.","journal-title":"Lancet"},{"issue":"1","key":"928_CR3","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach F, Baigent C, Catapano AL, et al. 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111\u201388.","journal-title":"Eur Heart J"},{"key":"928_CR4","first-page":"5","volume":"19","author":"F Stoll","year":"2020","unstructured":"Stoll F, Eidam A, Bauer JM, et al. Management of dyslipidaemia in the elderly. e-J Cardiol Pract. 2020;19:5.","journal-title":"e-J Cardiol Pract."},{"key":"928_CR5","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.atherosclerosis.2021.02.001","volume":"323","author":"MT Suadoni","year":"2021","unstructured":"Suadoni MT. Benefits and harms of LDL-cholesterol-lowering therapy in older people must be established through valid and clinically relevant evidence. Atherosclerosis. 2021;323:57\u20138.","journal-title":"Atherosclerosis"},{"key":"928_CR6","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.atherosclerosis.2020.11.029","volume":"317","author":"JK Stock","year":"2021","unstructured":"Stock JK. Should we treat high LDL cholesterol in \u201chealthy\u201d elderly individuals? Atherosclerosis. 2021;317:50\u20131.","journal-title":"Atherosclerosis"},{"issue":"10263","key":"928_CR7","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1016\/S0140-6736(20)32233-9","volume":"396","author":"MB Mortensen","year":"2020","unstructured":"Mortensen MB, Nordestgaard BG. Elevated LDL cholesterol and increased risk of myocardial infarction and atherosclerotic cardiovascular disease in individuals aged 70\u2013100 years: a contemporary primary prevention cohort. Lancet. 2020;396(10263):1644\u201352.","journal-title":"Lancet"},{"issue":"9","key":"928_CR8","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1093\/qjmed\/hcp093","volume":"102","author":"D Scott","year":"2009","unstructured":"Scott D, Blizzard L, Fell J, et al. Statin therapy, muscle function and falls risk in community-dwelling older adults. QJM. 2009;102(9):625\u201333.","journal-title":"QJM"},{"issue":"27","key":"928_CR9","doi-asserted-by":"publisher","first-page":"2526","DOI":"10.1093\/eurheartj\/ehy182","volume":"39","author":"F Mach","year":"2018","unstructured":"Mach F, Ray KK, Wiklund O, et al. Adverse effects of statin therapy: perception vs the evidence\u2014focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract. Eur Heart J. 2018;39(27):2526\u201339.","journal-title":"Eur Heart J"},{"issue":"10","key":"928_CR10","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1111\/jgs.16037","volume":"67","author":"DQ Phan","year":"2019","unstructured":"Phan DQ, Duan L, Lam B, et al. Statin adherence and mortality in patients aged 80 years and older after acute myocardial infarction. J Am Geriatr Soc. 2019;67(10):2045\u20139.","journal-title":"J Am Geriatr Soc"},{"key":"928_CR11","doi-asserted-by":"publisher","first-page":"675","DOI":"10.2147\/PPA.S245365","volume":"14","author":"MV Ingersgaard","year":"2020","unstructured":"Ingersgaard MV, Helms Andersen T, Norgaard O, et al. Reasons for nonadherence to statins\u2014a systematic review of reviews. Patient Prefer Adherence. 2020;14:675\u201391.","journal-title":"Patient Prefer Adherence"},{"issue":"1","key":"928_CR12","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1111\/bcp.13797","volume":"85","author":"R Ofori-Asenso","year":"2019","unstructured":"Ofori-Asenso R, Ilomaki J, Tacey M, et al. Predictors of first-year nonadherence and discontinuation of statins among older adults: a retrospective cohort study. Br J Clin Pharmacol. 2019;85(1):227\u201335.","journal-title":"Br J Clin Pharmacol"},{"issue":"18","key":"928_CR13","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","volume":"376","author":"MS Sabatine","year":"2017","unstructured":"Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713\u201322.","journal-title":"N Engl J Med"},{"issue":"22","key":"928_CR14","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","volume":"379","author":"GG Schwartz","year":"2018","unstructured":"Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379(22):2097\u2013107.","journal-title":"N Engl J Med"},{"issue":"22","key":"928_CR15","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1001\/jama.2016.16951","volume":"316","author":"SJ Nicholls","year":"2016","unstructured":"Nicholls SJ, Puri R, Anderson T, et al. Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial. JAMA. 2016;316(22):2373\u201384.","journal-title":"JAMA"},{"issue":"8","key":"928_CR16","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1177\/2047487320902750","volume":"28","author":"P Sever","year":"2021","unstructured":"Sever P, Gouni-Berthold I, Keech A, et al. LDL-cholesterol lowering with evolocumab, and outcomes according to age and sex in patients in the FOURIER Trial. Eur J Prev Cardiol. 2021;28(8):805\u201312.","journal-title":"Eur J Prev Cardiol"},{"issue":"24","key":"928_CR17","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1093\/eurheartj\/ehz809","volume":"41","author":"PR Sinnaeve","year":"2020","unstructured":"Sinnaeve PR, Schwartz GG, Wojdyla DM, et al. Effect of alirocumab on cardiovascular outcomes after acute coronary syndromes according to age: an ODYSSEY OUTCOMES trial analysis. Eur Heart J. 2020;41(24):2248\u201358.","journal-title":"Eur Heart J"},{"key":"928_CR18","unstructured":"European Medicines Agency. Praluent, summary of product characteristics. 2020. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/praluent-epar-product-information_en.pdf. 2 June 2020."},{"key":"928_CR19","unstructured":"European Medicines Agency. Repatha, summary of product characteristics. 2020. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/repatha-epar-product-information_en.pdf. 14 Apr 2020."},{"issue":"18","key":"928_CR20","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1016\/j.jacc.2020.03.039","volume":"75","author":"B Gencer","year":"2020","unstructured":"Gencer B, Mach F, Guo J, et al. Cognition after lowering LDL-cholesterol with evolocumab. J Am Coll Cardiol. 2020;75(18):2283\u201393.","journal-title":"J Am Coll Cardiol"},{"key":"928_CR21","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.atherosclerosis.2021.06.913","volume":"331","author":"MJ Janik","year":"2021","unstructured":"Janik MJ, Urbach DV, van Nieuwenhuizen E, et al. Alirocumab treatment and neurocognitive function according to the CANTAB scale in patients at increased cardiovascular risk: a prospective, randomized, placebo-controlled study. Atherosclerosis. 2021;331:20\u20137.","journal-title":"Atherosclerosis"},{"issue":"16","key":"928_CR22","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1056\/NEJMoa1701488","volume":"376","author":"PM Ridker","year":"2017","unstructured":"Ridker PM, Revkin J, Amarenco P, et al. Cardiovascular efficacy and safety of bococizumab in high-risk patients. N Engl J Med. 2017;376(16):1527\u201339.","journal-title":"N Engl J Med"},{"key":"928_CR23","unstructured":"European Medicines Agency. Leqvio, summary of product characteristics. 2020. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/leqvio-epar-product-information_en.pdf. 9 Dec 2020."},{"key":"928_CR24","doi-asserted-by":"publisher","first-page":"A16427","DOI":"10.1161\/circ.142.suppl_3.16427","volume":"142","author":"RSS Wright","year":"2020","unstructured":"Wright RSS, Ray KK, Raal FJ, et al. Abstract 16427: efficacy and safety of Inclisiran according to age: a pooled analysis of phase III studies (ORION 9, 10 and 11). AHA Scientific Sessions 2020. Circulation. 2020;142:A16427. https:\/\/doi.org\/10.1161\/circ.142.suppl_3.16427.","journal-title":"Circulation"},{"issue":"16","key":"928_CR25","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1056\/NEJMoa1913805","volume":"382","author":"FJ Raal","year":"2020","unstructured":"Raal FJ, Kallend D, Ray KK, et al. Inclisiran for the treatment of heterozygous familial hypercholesterolemia. N Engl J Med. 2020;382(16):1520\u201330.","journal-title":"N Engl J Med"},{"issue":"16","key":"928_CR26","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","volume":"382","author":"KK Ray","year":"2020","unstructured":"Ray KK, Wright RS, Kallend D, et al. Two phase 3 trials of Inclisiran in patients with elevated LDL cholesterol. N Engl J Med. 2020;382(16):1507\u201319.","journal-title":"N Engl J Med"},{"issue":"1","key":"928_CR27","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1093\/cvr\/cvaa077","volume":"117","author":"U Landmesser","year":"2021","unstructured":"Landmesser U, Haghikia A, Leiter LA, et al. Effect of inclisiran, the small-interfering RNA against proprotein convertase subtilisin\/kexin type 9, on platelets, immune cells, and immunological biomarkers: a pre-specified analysis from ORION-1. Cardiovasc Res. 2021;117(1):284\u201391.","journal-title":"Cardiovasc Res"},{"key":"928_CR28","unstructured":"European Medicines Agency. Nilemdo, summary of product characteristics. 2020. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/nilemdo-epar-product-information_en.pdf. 1 Apr 2020."},{"key":"928_CR29","unstructured":"European Medicines Agency. Nustendi, summary of product characteristics. 2020. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/nustendi-epar-product-information_en.pdf. 27 Mar 2020."},{"key":"928_CR30","doi-asserted-by":"publisher","first-page":"13457","DOI":"10.1038\/ncomms13457","volume":"7","author":"SL Pinkosky","year":"2016","unstructured":"Pinkosky SL, Newton RS, Day EA, et al. Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis. Nat Commun. 2016;7:13457.","journal-title":"Nat Commun"},{"issue":"4","key":"928_CR31","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1007\/s10557-021-07147-5","volume":"35","author":"CM Ballantyne","year":"2021","unstructured":"Ballantyne CM, Bays H, Catapano AL, et al. Role of Bempedoic Acid in Clinical Practice. Cardiovasc Drugs Ther. 2021;35(4):853\u201364.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"15","key":"928_CR32","doi-asserted-by":"publisher","first-page":"e016262","DOI":"10.1161\/JAHA.119.016262","volume":"9","author":"A Di Minno","year":"2020","unstructured":"Di Minno A, Lupoli R, Calcaterra I, et al. Efficacy and safety of bempedoic acid in patients with hypercholesterolemia: systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc. 2020;9(15):e016262.","journal-title":"J Am Heart Assoc"},{"key":"928_CR33","unstructured":"US Food and Drug Administration. Nexletol, prescribing information. 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/211616s000lbl.pdf."},{"issue":"1","key":"928_CR34","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1080\/00016470052943928","volume":"71","author":"J Nestorson","year":"2000","unstructured":"Nestorson J, Movin T, Moller M, et al. Function after Achilles tendon rupture in the elderly: 25 patients older than 65 years followed for 3 years. Acta Orthop Scand. 2000;71(1):64\u20138.","journal-title":"Acta Orthop Scand"},{"issue":"4","key":"928_CR35","first-page":"320","volume":"10","author":"A Ekram","year":"2021","unstructured":"Ekram A, Woods RL, Britt C, et al. The association between frailty and all-cause mortality in community-dwelling older individuals: an umbrella review. J Frailty Aging. 2021;10(4):320\u20136.","journal-title":"J Frailty Aging"},{"issue":"1","key":"928_CR36","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1080\/17425255.2021.1839413","volume":"17","author":"D Maher","year":"2021","unstructured":"Maher D, Ailabouni N, Mangoni AA, et al. Alterations in drug disposition in older adults: a focus on geriatric syndromes. Expert Opin Drug Metab Toxicol. 2021;17(1):41\u201352.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"928_CR37","unstructured":"European Medicines Agency. Reflection paper on physical frailty: instruments for baseline characterisation of older populations in clinical trials. 2018. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/reflection-paper-physical-frailty-instruments-baseline-characterisation-older-populations-clinical_en.pdf. 9 Jan 2018."},{"issue":"8","key":"928_CR38","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1016\/j.clinthera.2015.05.505","volume":"37","author":"K Iglay","year":"2015","unstructured":"Iglay K, Cao X, Mavros P, et al. Systematic literature review and meta-analysis of medication adherence with once-weekly versus once-daily therapy. Clin Ther. 2015;37(8):1813\u201321.","journal-title":"Clin Ther"},{"issue":"9","key":"928_CR39","doi-asserted-by":"publisher","first-page":"e14060","DOI":"10.1111\/ijcp.14060","volume":"75","author":"ER Weeda","year":"2021","unstructured":"Weeda ER, Muraoka AK, Brock MD, et al. Medication adherence to injectable glucagon-like peptide-1 (GLP-1) receptor agonists dosed once weekly vs once daily in patients with type 2 diabetes: a meta-analysis. Int J Clin Pract. 2021;75(9):e14060.","journal-title":"Int J Clin Pract"},{"issue":"6","key":"928_CR40","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.clpt.2006.09.003","volume":"80","author":"PJ Neuvonen","year":"2006","unstructured":"Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther. 2006;80(6):565\u201381.","journal-title":"Clin Pharmacol Ther"},{"issue":"7859","key":"928_CR41","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/s41586-021-03534-y","volume":"593","author":"K Musunuru","year":"2021","unstructured":"Musunuru K, Chadwick AC, Mizoguchi T, et al. In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates. Nature. 2021;593(7859):429\u201334.","journal-title":"Nature"}],"container-title":["Drugs & Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-022-00928-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40266-022-00928-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-022-00928-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,10]],"date-time":"2022-04-10T10:15:02Z","timestamp":1649585702000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40266-022-00928-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,12]]},"references-count":41,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["928"],"URL":"https:\/\/doi.org\/10.1007\/s40266-022-00928-z","relation":{},"ISSN":["1170-229X","1179-1969"],"issn-type":[{"value":"1170-229X","type":"print"},{"value":"1179-1969","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,12]]},"assertion":[{"value":"13 February 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No external funding was used in the preparation of this manuscript. Open Access funding was enabled and organized by Projekt DEAL.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Felicitas Stoll, Annette Eidam\u00a0and Lola Michael have no potential conflicts of interest that might be relevant to the contents of this manuscript. J\u00fcrgen M. Bauer has\u00a0received speaker honoraria from Novartis, Pfizer, Bayer and UCB Pharma; all\u00a0income from these activities go to his institution.\u00a0Walter E. Haefeli has received honoraria from Daiichi-Sankyo, the manufacturer of bempedoic acid, for lectures and grants to conduct drug interaction trials unrelated to this topic.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Felicitas Stoll: data collection, writing. Annette Eidam, Lola Michael, J\u00fcrgen M. Bauer, and Walter E. Haefeli: reviewing.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}